Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - rasagiline - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - rasagiline tartrate - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - rasagiline - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - rasagiline tartrate - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: citric acid; purified talc; pregelatinised maize starch; silicon dioxide; maize starch; microcrystalline cellulose; stearic acid - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: citric acid; stearic acid; pregelatinised maize starch; maize starch; microcrystalline cellulose; silicon dioxide; purified talc - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: purified talc; stearic acid; citric acid; silicon dioxide; microcrystalline cellulose; pregelatinised maize starch; maize starch - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: silicon dioxide; microcrystalline cellulose; stearic acid; purified talc; maize starch; citric acid; pregelatinised maize starch - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: silicon dioxide; pregelatinised maize starch; citric acid; maize starch; stearic acid; microcrystalline cellulose; purified talc - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - rasagiline tartrate 1,44 mg - eq. rasagiline 1 mg - tablet - 1 mg - rasagiline tartrate 1.44 mg - rasagiline